China’s National Healthcare Security Administration has unveiled groundbreaking pricing guidelines for brain-computer interface (BCI) technologies, signaling a major step toward integrating this cutting-edge innovation into mainstream healthcare. Released Wednesday, the guidelines outline standardized fees for both invasive implantation and non-invasive adaptation of BCI systems, creating clarity for hospitals and developers.
Breakthroughs in Neurotech
BCI enables direct communication between the brain and external devices through electrodes or sensors. While global players like Neuralink focus on fully invasive implants, Chinese researchers have pioneered semi-invasive solutions. Tsinghua University’s Neural Electronic Opportunity (NEO) device, led by Professor Hong Bo, sits between the skull and dura mater, minimizing tissue damage while maintaining high signal quality.
From Lab to Clinic
The NEO system has already shown promise in clinical trials. At Beijing’s Capital Medical University Xuanwu Hospital, a paralyzed patient regained hand motion using an air-controlled glove linked to the device. Three patients have undergone NEO implantation, with plans to scale to 30-50 cases by 2025. A production line in Shanghai’s Zhangjiang Cell Industrial Park aims to manufacture 10,000 units annually, boosting accessibility.
Next-Gen Innovations
Hong’s team is refining a coin-sized prototype with 64 signal channels, lighter materials, and advanced chips. “This evolution will make BCIs safer and more adaptable for diverse medical applications,” he noted. Analysts suggest the pricing framework could accelerate investment in neurotech across Asia.
